Alnylam Pharmaceuticals
ALNY
#581
Rank
A$55.13 B
Marketcap
$426.02
Share price
-0.94%
Change (1 day)
85.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.52. In 2022 the company made an earnings per share (EPS) of -$14.74 a decrease over its 2021 EPS that were of -$11.43.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-58.92%
2022-$14.7429.03%
2021-$11.43-3.36%
2020-$11.82-8.48%
2019-$12.927.67%
2018-$12.0039.74%
2017-$8.5912.94%
2016-$7.6038.84%
2015-$5.47-32.88%
2014-$8.16259.44%
2013-$2.27-31.25%
2012-$3.3052.94%
2011-$2.1630.77%
2010-$1.65-8.77%
2009-$1.8178.13%
2008-$1.02-70.78%
2007-$3.4899.09%
2006-$1.75-43.88%
2005-$3.11-82.33%
2004-$17.60-59.23%
2003-$43.18

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.70-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$59.29-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.43 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.43-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.68-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.94-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.05-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.17-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel